Remus Pharmaceuticals Limited has announced that the audio recording of its earnings conference call is now available for stakeholders. The meeting was held on May 21, 2026, to discuss the audited financial results for the half year and financial year ended March 31, 2026.

The disclosure was made in compliance with Regulations 30 and 46 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The conference call included analysts, institutional investors, funds, and other investors.

Accessing the Recording

Investors and interested parties can access the audio recording of the conference call through the official website of remus pharmaceuticals . The specific web link provided for access is https://remuspharma.com/investor-meet/ .

Key Disclosures

The company confirmed that no unpublished price sensitive information was shared or discussed during the earnings conference call. The proceedings were focused on the financial performance for the specified periods.

The communication was addressed to the Manager of the Listing Department at the National Stock Exchange of India Limited to ensure the information is placed on record.

Remus Pharmaceuticals Limited has appointed Mr. Tapan Shah as its Secretarial Auditor for the financial year 2026-2027. The decision was taken by the Board of Directors during a meeting held on May 20, 2026, based on the recommendation of the Audit Committee.

Appointment Details

The appointment of Mr. Tapan Shah, a Practicing Company Secretary, was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. He has been assigned the task of conducting the Secretarial Audit for the company for the specified financial year.

Auditor Profile

Mr. Tapan Shah holds a Certificate of Practice No. 2839 and Membership No. FCS 4476. He is a peer-reviewed practicing Company Secretary with over 25 years of experience. His professional background includes providing services to listed companies, SMEs, multinational corporations, Section 8 entities, and LLPs. His expertise covers corporate laws, SEBI laws, stock exchange matters, and various regulatory compliance services.

The company confirmed that there are no relationships between Mr. Tapan Shah and the directors of the company that require disclosure under the relevant regulations. The appointment is effective from May 20, 2026.